TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33141936
Drug: High-trigger transfusion
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-trigger transfusion (haemoglobin below 9.7 g/dL)
Study: 33744844
Drug: Health IT
Normalized name: DIPHENHYDRAMINE HYDROCHLORIDE 2 mg in 100 mL TOPICAL GEL [A Health Itch Relief Gel]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health IT intervention using the Patient Buddy app focusing on ascites, medications, and hepatic encephalopathy over 30 days.
Study: 34792188
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with Dermatophagoides farinae drops
Study: 34792188
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (topical glucocorticoids, skin moisturizers, oral antihistamines, allergen avoidance)
Study: 34710894
Drug: Individual Metacognitive
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual Metacognitive Interpersonal Therapy (MIT) combined with Group Mentalization-Based Treatment (MBT)
Study: 36084129
Drug: Cultural adaptation
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cultural adaptation promotion resilience program (CAPRP), performed for 60 minutes, twice a week for four weeks
Study: 33125944
Drug: IMRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMRT with cetuximab and avelumab (10 mg/kg day 7 and every 2 weeks) followed by avelumab every two weeks for 12 months (arm B and C)
Study: 33125944
Drug: Intensity Modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity Modulated Radiation Therapy (IMRT) with cisplatin (100 mg/m2 Q3W) (arm A)
Study: 33125944
Drug: Intensity Modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity Modulated Radiation Therapy (IMRT) with weekly cetuximab (arm D)
Study: 33326576
Drug: HPV-vaccine arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV-vaccine arm
Study: 36042627
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (10 g/d) with resistance training (3 times a week)
Study: 36042627
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 g/d) with resistance training (3 times a week)
Study: 35658926
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptives (Control)
Study: 34913959
Drug: Apatinib 500
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 500 mg/d
Study: 33289973
Drug: Hydroxychloroquine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (800 mg once, followed by 400 mg daily for 6 days)
Study: 33289973
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (no specific therapy)
Study: 35982468
Drug: Optional combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optional combined interventions (multi-media messages, nicotine replacement therapy sampling, financial incentive for active referral, phone counselling, and family/peer support group chat)
Study: 32350792
Drug: Non-vitamin K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-vitamin K oral anticoagulants (NOACs) such as apixaban and edoxaban
Study: 32901243
Drug: Desensitizing-containing hydrogen
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desensitizing-containing hydrogen peroxide gel (5% potassium nitrate)
Study: 32901243
Drug: Desensitizing-free hydrogen
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desensitizing-free hydrogen peroxide gel (35%)
Study: 33842864
Drug: Rapid-test-guided treatment
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid-test-guided treatment for ASB
Study: 32445190
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg Δ9-THC
Study: 32445190
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg Δ9-THC
Study: 32004693
Drug: Vi-DT Typhoid
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi-DT Typhoid Conjugate Vaccine
Study: 35676445
Drug: Multimodal deep
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal deep learning architecture for therapy personalization
Study: 33784987
Drug: Lung-protective ventilation
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung-protective ventilation (LPV) with a tidal volume (Vt) of 7 ml kg−1 ideal body weight (IBW), 10 cmH2O positive end-expiratory pressure (PEEP) combined with regular recruitment maneuvers (RMs)
Study: 33784987
Drug: Conventional ventilation
Normalized name: VENTILATOR FILTER,THERMOFLO #6000S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional ventilation (CV) with a Vt of 10 ml kg−1 IBW, 0 cmH2O in PEEP and no RMs
Study: 33128399
Drug: Combination with
Normalized name: Iron in combination with folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination with Autogenous Bone Grafts (AG)
Study: 33128399
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mPPT and AG
Study: 33128399
Drug: rhFGF-2 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhFGF-2 therapy
Study: 32363638
Drug: Gabapentin (GBP)
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin (GBP) 100 mg/day orally for 6 weeks
Study: 32363638
Drug: Hydroxyzine (HYDZ)
Normalized name: Hydroxizine
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxyzine (HYDZ) 25 mg/day orally for 6 weeks
Study: 33541495
Drug: rhTPO 15,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhTPO 15,000 U, once daily for 7 days
Study: 32337693
Drug: Sheng Xue
Normalized name: Ji Xue Cao Whole
DrugBank: Centella asiatica (DB14256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sheng Xue Ning (SXN) tablets
Study: 32337693
Drug: Ferrous succinate
Normalized name: Ferrous succinate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous succinate (FS) tablets
Study: 33899450
Drug: ALMAG +
Normalized name: almagate
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALMAG + magnetic therapy device
Study: 32484754
Drug: Standard-of-care (SOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care (SOC) treatments (arm 1)
Study: 34479861
Drug: Control (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (twice with SP)
Study: 32579813
Drug: Hydroxyurea with
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea with dose escalation (approximately 30 mg per kilogram per day)
Study: 32579813
Drug: Hydroxyurea at
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea at a fixed dose (approximately 20 mg per kilogram of body weight per day)
Study: 32579813
Drug: Dose escalation
Normalized name: PALFORZIA Initial Dose Escalation KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation group
Study: 615918278
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection (IAI) 2.0 mg every 8 weeks after 3 initial monthly doses (2q8)
Study: 35114057
Drug: acute treatment-related
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: acute treatment-related toxicity
Study: 32744358
Drug: metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin + PEX168 100 μg
Study: 32744358
Drug: metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin + PEX168 200 μg
Study: 35272403
Drug: High-frequency acupuncture
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency acupuncture (5 times weekly for weeks 1-4, 3 times weekly for weeks 5-8)
Study: 35272403
Drug: Low-frequency acupuncture
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency acupuncture (3 times weekly for weeks 1-4, 2 times weekly for weeks 5-8)
Study: 33860924
Drug: Vericiguat plus
Normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vericiguat plus guideline-directed medical therapy (GDMT)
Study: 33860924
Drug: Guideline-directed medical
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-directed medical therapy (GDMT) plus placebo
Study: 33091174
Drug: High fermentable
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fermentable fiber intake (13 g)
Study: 33091174
Drug: Low fermentable
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fermentable fiber intake (≤ 2 g)
Study: 36691173
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of 11.4 mg betamethasone
Study: 34627611
Drug: DMUC4064A (5.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMUC4064A (5.2 mg/kg RP2D)
Study: 34627611
Drug: DMUC4064A (≥3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMUC4064A (≥3.2 mg/kg)
Study: 32174632
Drug: Bach flower
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bach flower therapy (BFT)
Study: 35508656
Drug: Intermittent dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent dosing of PI3Kδi
Study: 34558835
Drug: Ipragliflozin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipragliflozin (50 mg/day for 72 weeks)
Study: 34558835
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no SGLT2is, pioglitazone, GLP-1 analogs, or insulin)
Study: 36241463
Drug: Pitavastatin 2
Normalized name: PITAVASTATIN 2MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 2 mg plus ezetimibe 10 mg
Study: 36241463
Drug: Pitavastatin 4
Normalized name: PITAVASTATIN 4MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 4 mg plus ezetimibe 10 mg
Study: 35392963
Drug: Probenecid (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probenecid (1 g orally twice per day for 180 days)
Study: 34115990
Drug: Dose Optimization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Optimization for Stone Evaluation intervention (customized CME modules, personalized consultation, and protocol recommendations for RDCT)
Study: 36217872
Drug: Inclisiran sodium
Normalized name: inclisiran sodium
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inclisiran sodium 300 mg/284 mg (free acid) administered at days 1, 90, 270 and 450
Study: 32703194
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine drops (5 mg, four daily doses for 1 week)
Study: 35384021
Drug: Low-dose rituximab
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rituximab (500 mg, 2 weeks apart)
Study: 35384021
Drug: Rheumatoid arthritis
Normalized name: Rheumatoid arthritis nuclear antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rheumatoid arthritis protocol (1000 mg given as two doses, 2 weeks apart)
Study: 35384021
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received short-term oral corticosteroids
Study: 32268815
Drug: Pomalidomide, bortezomib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide, bortezomib, and low-dose dexamethasone (PVd)
Study: 32268815
Drug: Bortezomib and
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib and low-dose dexamethasone (Vd)
Study: 34459271
Drug: Education (brief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education (brief psychoeducation and treatment resources)
Study: 34459271
Drug: Education+Motivation (Education
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education+Motivation (Education plus treatment seeking-focused motivational content)
Study: 32078787
Drug: AkP05 nutraceutical
Normalized name: ZINC OXIDE 154 mg in 1 mL TOPICAL LOTION [Ultraceuticals Ultra UV Protective Daily Moisturising]
Approvals — FDA: no, EMA: no, PMDA: no
Description: AkP05 nutraceutical combination
Study: 33249593
Drug: high-dose rhIGF‐1/rhIGFBP‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-dose rhIGF‐1/rhIGFBP‐3 (60 mg/day)
Study: 33249593
Drug: low-dose rhIGF‐1/rhIGFBP‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: low-dose rhIGF‐1/rhIGFBP‐3 (30 mg/day)
Study: 35462371
Drug: Sodium zirconium
Normalized name: Sodium zirconium silicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sodium zirconium cyclosilicate (SZC) 10 g once daily during the maintenance phase
Study: 36043350
Drug: Fluoxetine 10
Normalized name: fluoxetine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 10 mg once daily for 12 weeks
Study: 32632763
Drug: Face-to-face treatment
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face treatment (10 sessions, 60 minutes each)
Study: 32632763
Drug: Low-intensity treatment
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity treatment (information delivered in printed or electronic format, supported by up to four telephone sessions)
Study: 35450913
Drug: Complex continuum
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex continuum of care intervention delivered by community health workers, including health literacy material, multimicronutrient supplement, health services, feedback, and behaviour change support sessions.
Study: 35062988
Drug: Naoxintong capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naoxintong capsules (NXT)
Study: 32007169
Drug: Pharmacological cardioversion
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological cardioversion followed by electrical cardioversion (drug-shock)
Study: 32007169
Drug: Drug infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug infusion only (part of drug-shock group)
Study: 34896904
Drug: Probiotics (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (three capsules, twice/day)
Study: 32643886
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium double-release enteric-coated capsules and Fugui Gutong capsules
Study: 33010112
Drug: Axitinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib (5 mg orally twice daily)
Study: 36049050
Drug: Gut microbiome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gut microbiome L-tryptophan biosynthesis during acute COVID-19
Study: 36167574
Drug: Inhalation anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation anesthesia with sevoflurane
Study: 35150590
Drug: Denture disinfecting
Normalized name: ALCOHOL,DENATURED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denture disinfecting tablets
Study: 35150590
Drug: Denture disinfecting
Normalized name: ALCOHOL,DENATURED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denture disinfecting tablets plus palatine mucosa brushing solution
Study: 32448992
Drug: Wheat soya
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat soya blend plus (WSBP) provided during pregnancy and lactation (5 kg/month, 165 g/day)
Study: 32827193
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (topical corticosteroids + antibiotics)
Study: 32827193
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids treatment
Study: 34369693
Drug: Donepezil, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil, 5 mg once a day for 4 weeks
Study: 32592571
Drug: Shock wave
Normalized name: ELECTRODE GEL,H-WAVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shock wave therapy (SVT) + transcerebral magnetotherapy
Study: 32592571
Drug: Shock wave
Normalized name: ELECTRODE GEL,H-WAVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shock wave therapy (SVT)
Study: 34976102
Drug: Lateral Direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral Direct Anterior Approach (L-DAA)
Study: 33067484
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all MRI sequences excluding ADC map
Study: 32545250
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D supplementation of 400 IU/day
Study: 38886836
Drug: Bevacizumab-based chemotherapy
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab-based chemotherapy
Study: 32671536
Drug: Nasogastric tube
Normalized name: nasogastric tube
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasogastric tube with Gastrografin (NGT-G)
Study: 32445474
Drug: Intrapartum oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapartum oral azithromycin
Study: 32512963
Drug: AHH group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: AHH group (6% hydroxyethyl starch 130/0.4 at a rate of 20 ml/min after anesthesia induction)
Study: 35201607
Drug: Extended-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release methylphenidate
Study: 35988587
Drug: CYP2C19 genotype-guided
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2C19 genotype-guided antithrombotic treatment (clopidogrel 75 mg for normal metabolizers, clopidogrel 150 mg for intermediate metabolizers, acetylsalicylic acid 80 mg plus rivaroxaban 2.5 mg for poor metabolizers)
Study: 35988587
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg once daily (control group)
Study: 35988587
Drug: CYP2C19 genotype-guided
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2C19 genotype-guided antithrombotic treatment
Study: 35379380
Drug: Prophylactic amoxicillin‐clavulanic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic amoxicillin‐clavulanic acid (0.375 mg/mL) for 14 days
Study: 35379380
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of C. bovis inoculation and oral antibiotics (Cb+Abx+)
Study: 32868370
Drug: Antibody
Normalized name: Antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody
Study: 34187478
Drug: Genetically mimicking
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically mimicking PCSK9 inhibitors or ezetimibe
Study: 39425917
Drug: Arginine infusion
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine infusion
Study: 34482319
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C and thiamine for 48 hours
Study: 35503768
Drug: Cycling (altering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycling (altering first-line empiric therapy for Gram-negative bacteria every other 6-weeks)
Study: 35503768
Drug: Mixing (changing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixing (changing antibiotic type every empiric antibiotic course)
Study: 36253903
Drug: Low-fat, vegan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat, vegan diet and cooked soybeans (½ cup [86 g] daily)
Study: 32394874
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with liposomal amphotericin B (7.5 mg/kg, single dose) and short-course miltefosine (2.5 mg/kg/day for 14 days)
Study: 32394874
Drug: Miltefosine monotherapy
Normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miltefosine monotherapy (2.5 mg/kg/day for 28 days)
Study: 35939920
Drug: V‐NeST plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: V‐NeST plus treatment as‐usual (TAU)
Study: 33914314
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (1.5 mg/kg) + 50 mg dexketoprofen in 10 mL saline, administered 30 min before the procedure.
Study: 33914314
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 50 mg dexketoprofen in 10 mL saline, administered 30 min before the procedure.
Study: 35313167
Drug: Adjuvant pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjuvant pertuzumab (P) added to trastuzumab and chemotherapy
Study: 35313167
Drug: Placebo (Pla)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Pla) added to trastuzumab and chemotherapy
Study: 32859662
Drug: Tailored multistep
Normalized name: MultiStem
DrugBank: MultiStem (DB15742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored multistep intervention (IA) incorporating electronic PRO assessment, case vignette, and expert-consented treatment recommendations
Study: 35551600
Drug: AD036 (atomoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: AD036 (atomoxetine 80 mg and oxybutynin 5 mg)
Study: 35551600
Drug: Atomoxetine 80
Normalized name: atomoxetine 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine 80 mg alone
Study: 34238537
Drug: Adapted glass
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted glass fiber post with post space preparation of the same size
Study: 33004790
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g whey protein drink (120 kcal)
Study: 32346686
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg ZOL with calcitriol and calcium carbonate